Skip to main content

Table 1 Response to treatment according to CD15/FUT4-IHC on primary tumors and NLR at diagnosis

From: Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer

 

CD15/FUT4-IHC

NLR at diagnosis

Therapeutic response

Neg

Low

High

P

NLR ≤5

NLR >5

P

Frequency

N

(%)

N

(%)

N

(%)

0.00000532

N

(%)

N

(%)

0.00012545

Responder

17

(94)

32

(80)

13

(30)

 

28

(93)

34

(47)

 

Nonresponder

1

(6)

8

(20)

31

(70)

 

2

(7)

38

(53)

 

Total

18

(100)

40

(100)

44

(100)

 

30

(100)

72

(100)

 
  1. Abbreviation: IHC immunohistochemistry, NLR blood neutrophil-to-lymphocyte ratio